Peringatan Keamanan

-RISK OF THYROID C-CELL TUMORS
-Albiglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with Albiglutide.

Albiglutide

DB09043

biotech approved

Deskripsi

Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 4-7 days.
Volume Distribusi 11 L.
Klirens (Clearance) 67 mL/h.

Absorpsi

Maximum concentrations of albiglutide were reached at 3 to 5 days post-dosing following a single 30mg dose. The mean peak concentration (Cmax) and mean area under the time-concentration curve (AUC) of albiglutide were 1.74 mcg/mL and 465 mcg.h/mL, respectively

Metabolisme

Biotransformation studies have not been performed. Because albiglutide is an albumin fusion protein, it likely follows a metabolic pathway similar to native human serum albumin, which is catabolized primarily in the vascular endothelium.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

603 Data
Pegvisomant The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Albiglutide.
Lipoic acid The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Albiglutide.
Moxifloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Moxifloxacin.
Grepafloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Grepafloxacin.
Enoxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Enoxacin.
Pefloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Pefloxacin.
Ciprofloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Ciprofloxacin.
Trovafloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Trovafloxacin.
Nalidixic acid The therapeutic efficacy of Albiglutide can be increased when used in combination with Nalidixic acid.
Rosoxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Rosoxacin.
Cinoxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Cinoxacin.
Lomefloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Lomefloxacin.
Gatifloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Gatifloxacin.
Norfloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Norfloxacin.
Levofloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Levofloxacin.
Gemifloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Gemifloxacin.
Ofloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Ofloxacin.
Sparfloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Sparfloxacin.
Temafloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Temafloxacin.
Fleroxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Fleroxacin.
Technetium Tc-99m ciprofloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Technetium Tc-99m ciprofloxacin.
Garenoxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Garenoxacin.
Nemonoxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Nemonoxacin.
Flumequine The therapeutic efficacy of Albiglutide can be increased when used in combination with Flumequine.
Enrofloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Enrofloxacin.
Orbifloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Orbifloxacin.
Sarafloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Sarafloxacin.
Difloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Difloxacin.
Pazufloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Pazufloxacin.
Prulifloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Prulifloxacin.
Delafloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Delafloxacin.
Sitafloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Sitafloxacin.
Oxolinic acid The therapeutic efficacy of Albiglutide can be increased when used in combination with Oxolinic acid.
Rufloxacin The therapeutic efficacy of Albiglutide can be increased when used in combination with Rufloxacin.
Pipemidic acid The therapeutic efficacy of Albiglutide can be increased when used in combination with Pipemidic acid.
Methyclothiazide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Methyclothiazide.
Chlorthalidone The therapeutic efficacy of Albiglutide can be decreased when used in combination with Chlorthalidone.
Bendroflumethiazide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Bendroflumethiazide.
Metolazone The therapeutic efficacy of Albiglutide can be decreased when used in combination with Metolazone.
Benzthiazide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Benzthiazide.
Hydroflumethiazide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Hydroflumethiazide.
Indapamide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Indapamide.
Chlorothiazide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Chlorothiazide.
Hydrochlorothiazide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Hydrochlorothiazide.
Trichlormethiazide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Trichlormethiazide.
Polythiazide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Polythiazide.
Quinethazone The therapeutic efficacy of Albiglutide can be decreased when used in combination with Quinethazone.
Cyclopenthiazide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Cyclopenthiazide.
Epitizide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Epitizide.
Amitriptyline Amitriptyline may decrease the hypoglycemic activities of Albiglutide.
Protriptyline Protriptyline may decrease the hypoglycemic activities of Albiglutide.
Imipramine Imipramine may decrease the hypoglycemic activities of Albiglutide.
Nortriptyline Nortriptyline may decrease the hypoglycemic activities of Albiglutide.
Amoxapine Amoxapine may decrease the hypoglycemic activities of Albiglutide.
Trimipramine Trimipramine may decrease the hypoglycemic activities of Albiglutide.
Doxepin Doxepin may decrease the hypoglycemic activities of Albiglutide.
Desipramine Desipramine may decrease the hypoglycemic activities of Albiglutide.
Clomipramine Clomipramine may decrease the hypoglycemic activities of Albiglutide.
Amineptine Amineptine may decrease the hypoglycemic activities of Albiglutide.
Dimetacrine Dimetacrine may decrease the hypoglycemic activities of Albiglutide.
Butriptyline Butriptyline may decrease the hypoglycemic activities of Albiglutide.
Dosulepin Dosulepin may decrease the hypoglycemic activities of Albiglutide.
Tianeptine Tianeptine may decrease the hypoglycemic activities of Albiglutide.
Oxaprotiline Oxaprotiline may decrease the hypoglycemic activities of Albiglutide.
Opipramol Opipramol may decrease the hypoglycemic activities of Albiglutide.
Amitriptylinoxide Amitriptylinoxide may decrease the hypoglycemic activities of Albiglutide.
Dibenzepin Dibenzepin may decrease the hypoglycemic activities of Albiglutide.
Quinupramine Quinupramine may decrease the hypoglycemic activities of Albiglutide.
Melitracen Melitracen may decrease the hypoglycemic activities of Albiglutide.
Lofepramine Lofepramine may decrease the hypoglycemic activities of Albiglutide.
Iprindole Iprindole may decrease the hypoglycemic activities of Albiglutide.
Imipramine oxide Imipramine oxide may decrease the hypoglycemic activities of Albiglutide.
Glimepiride Albiglutide may increase the hypoglycemic activities of Glimepiride.
Acetohexamide Albiglutide may increase the hypoglycemic activities of Acetohexamide.
Chlorpropamide Albiglutide may increase the hypoglycemic activities of Chlorpropamide.
Tolazamide Albiglutide may increase the hypoglycemic activities of Tolazamide.
Glyburide Albiglutide may increase the hypoglycemic activities of Glyburide.
Glipizide Albiglutide may increase the hypoglycemic activities of Glipizide.
Gliclazide Albiglutide may increase the hypoglycemic activities of Gliclazide.
Tolbutamide Albiglutide may increase the hypoglycemic activities of Tolbutamide.
Gliquidone Albiglutide may increase the hypoglycemic activities of Gliquidone.
Glisoxepide Albiglutide may increase the hypoglycemic activities of Glisoxepide.
Glibornuride Albiglutide may increase the hypoglycemic activities of Glibornuride.
Carbutamide Albiglutide may increase the hypoglycemic activities of Carbutamide.
Metahexamide Albiglutide may increase the hypoglycemic activities of Metahexamide.
Dapagliflozin Dapagliflozin may increase the hypoglycemic activities of Albiglutide.
Canagliflozin Canagliflozin may increase the hypoglycemic activities of Albiglutide.
Leuprolide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide.
Goserelin The therapeutic efficacy of Albiglutide can be decreased when used in combination with Goserelin.
Nelfinavir The therapeutic efficacy of Albiglutide can be decreased when used in combination with Nelfinavir.
Indinavir The therapeutic efficacy of Albiglutide can be decreased when used in combination with Indinavir.
Ziprasidone The therapeutic efficacy of Albiglutide can be decreased when used in combination with Ziprasidone.
Etonogestrel The therapeutic efficacy of Albiglutide can be decreased when used in combination with Etonogestrel.
Desogestrel The therapeutic efficacy of Albiglutide can be decreased when used in combination with Desogestrel.
Olanzapine The therapeutic efficacy of Albiglutide can be decreased when used in combination with Olanzapine.
Megestrol acetate The therapeutic efficacy of Albiglutide can be decreased when used in combination with Megestrol acetate.
Clozapine The therapeutic efficacy of Albiglutide can be decreased when used in combination with Clozapine.
Levonorgestrel The therapeutic efficacy of Albiglutide can be decreased when used in combination with Levonorgestrel.
Progesterone The therapeutic efficacy of Albiglutide can be decreased when used in combination with Progesterone.
Chlorpromazine The therapeutic efficacy of Albiglutide can be decreased when used in combination with Chlorpromazine.

Target Protein

Glucagon-like peptide 1 receptor GLP1R

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25136065
    Trujillo JM, Nuffer W: Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014 Nov;48(11):1494-501. doi: 10.1177/1060028014545807. Epub 2014 Aug 18.

Contoh Produk & Brand

Produk: 8 • International brands: 0
Produk
  • Eperzan
    Powder, for solution • 30 mg / 0.5 mL • Subcutaneous • Canada • Approved
  • Eperzan
    Powder, for solution • 50 mg / 0.5 mL • Subcutaneous • Canada • Approved
  • Eperzan
    Injection, powder, for solution • 30 mg • Subcutaneous • EU
  • Eperzan
    Injection, powder, for solution • 50 mg • Subcutaneous • EU
  • Eperzan
    Injection, powder, for solution • 30 mg • Subcutaneous • EU
  • Eperzan
    Injection, powder, for solution • 50 mg • Subcutaneous • EU
  • Tanzeum
    Injection, powder, lyophilized, for solution • 30 mg/0.5mL • Subcutaneous • US • Approved
  • Tanzeum
    Injection, powder, lyophilized, for solution • 50 mg/0.5mL • Subcutaneous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul